FTSE 100 Live Wednesday HSBC profit fallsBAE Systems ups guidanceTaylor Wimpey takes profit hit ...

GSK lifted profit guidance for the year on Wednesday after sales of the drugmaker's 'specialty' medicines soared.

Specialty Medicines delivered 15% growth to £3.3 billion, led by Respiratory, Immunology & Inflammation up 10%, Oncology up 42%, and HIV up 12%. CEO Emma Walmsley said the performance reflects “strong ...

British drugmaker GSK expects annual sales and profit to be towards the top of its forecast range, after second-quarter sales ...

(Alliance News) - GSK predicted an annual outturn at the top end of guidance, BAE Systems maintained its outlook, while Aston Martin softened its profit forecast. Here is what you need to know before ...

British pharmaceutical company GlaxoSmithKline on Wednesday said its annual performance should be better than expected, despite US tariffs, after sales of its cancer drugs jumped in the second quarter ...

British drugmaker GSK said on Wednesday it expects to report annual sales and profit towards the top end of its forecast ...

Shares of GSK fell to below $30 around the time of the demerger, but have since recovered to about $36. The 20% gain over 34 ...

GSK GSK stock has risen 21.5% in the past six months. The consistently strong performance of the Specialty Medicines unit, regulatory and pipeline successes and an optimistic outlook for the long ...

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

GSK and Hengrui Pharma signed a global deal for up to 12 drugs, including COPD therapy, with milestone payments totaling $12 ...

In the segment, while products like Nucala and Dovato are key top-line drivers, new long-acting HIV medicines, Cabenuva and Apretude, as well as new oncology drugs Jemperli and Ojjaara, are also ...